STRATA Skin Sciences Q1 2025 revenue $6.8M up 1%; net loss narrows to $2.4M

STRATA Skin Sciences, Inc.

2025-Q1 EPS reported -$0.58 vs consensus -$0.53 ▼ miss (-10.2%)

Revenue $6.8M (+1% YoY); gross margin expanded 790 bps to 53.5%.
Net loss $2.4M (EPS -$0.58) vs $3.4M loss (-$0.96) in Q1 2024.
Adjusted EBITDA improved to -$0.55M from -$1.3M; operating expenses fell 5% to $5.7M.
International revenue grew 8% YoY, now 36% of total; DTC drove 32% more psoriasis patients.
Cash at quarter-end $7.8M; operating cash flow improved to -$0.55M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.